Liraglutide vs Tesofensine
Head-to-head comparison of Liraglutide and Tesofensine for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Liraglutide | Tesofensine |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Weight Loss / Reuptake Inhibitor |
| Mechanism | Liraglutide binds to GLP-1 receptors on pancreatic β-cells, increasing intracellular cAMP and triggering glucose-dependent insulin secretion. | Tesofensine inhibits the presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing synaptic concentrations of all three monoamines. |
| Evidence Rating | A — FDA Approved | C — Phase II–III Clinical Trials |
| Clinical Status | FDA-approved (Victoza for T2D, Saxenda for obesity) | Phase 3 clinical trials (Saniona). Phase 2 completed with significant weight loss results. |
| Safety Profile | Common: nausea (39%), diarrhea (21%), constipation (19%), vomiting (15%), headache (13%); GI side effects are dose-dependent and typically diminish over weeks | Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses; Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea |
| Molecular Weight | ~3,751 g/mol | ~397.5 g/mol |
| Half-Life | ~13 hours | N/A |
Overview
Liraglutide and Tesofensine are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Liraglutide — Mechanism & Evidence
Liraglutide is an FDA-approved GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1. Developed by Novo Nordisk, it is approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was the first GLP-1 agonist approved for obesity. While effective, it has been largely superseded by semaglutide (once-weekly dosing, greater weight loss) — liraglutide requires daily injection and achieves approximately 8% weight loss vs semaglutide's 15%.
Key claims: Clinically significant weight loss; Improves glycemic control; Cardiovascular benefit.
Tesamorelin 10mg
10mg
Tesofensine — Mechanism & Evidence
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Alzheimer's and Parkinson's disease. The compound was developed by NeuroSearch A/S and later licensed to Saniona, which is pursuing Phase 3 trials.
Key claims: Produces significant weight loss (~10% body weight); Suppresses appetite and reduces caloric intake; Increases resting metabolic rate.
Shared Research Applications
These peptides target different research areas. Liraglutide focuses on Weight Management, Metabolic Health, Cardiovascular, while Tesofensine targets Weight Loss, Appetite Suppression.
Safety Considerations
Liraglutide: Common: nausea (39%), diarrhea (21%), constipation (19%), vomiting (15%), headache (13%) GI side effects are dose-dependent and typically diminish over weeks FDA black box warning for thyroid C-cell tumors (rodent data)
Tesofensine: Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea Psychiatric effects reported: anxiety, mood changes (consistent with monoamine reuptake inhibitors)
Shop Research Peptides
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.